Literature DB >> 27068471

CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

Zhen Wang1, Qinghua Pan2, Patrick Gendron3, Weijun Zhu4, Fei Guo4, Shan Cen5, Mark A Wainberg1, Chen Liang6.   

Abstract

Cas9 cleaves specific DNA sequences with the assistance of a programmable single guide RNA (sgRNA). Repairing this broken DNA by the cell's error-prone non-homologous end joining (NHEJ) machinery leads to insertions and deletions (indels) that often impair DNA function. Using HIV-1, we have now demonstrated that many of these indels are indeed lethal for the virus, but that others lead to the emergence of replication competent viruses that are resistant to Cas9/sgRNA. This unexpected contribution of Cas9 to the development of viral resistance is facilitated by some indels that are not deleterious for viral replication, but that are refractory to recognition by the same sgRNA as a result of changing the target DNA sequences. This observation illustrates two opposite outcomes of Cas9/sgRNA action, i.e., inactivation of HIV-1 and acceleration of viral escape, thereby potentially limiting the use of Cas9/sgRNA in HIV-1 therapy.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27068471     DOI: 10.1016/j.celrep.2016.03.042

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  102 in total

1.  A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness.

Authors:  K E Yoder
Journal:  Acta Virol       Date:  2019       Impact factor: 1.162

Review 2.  The multifaceted nature of HIV latency.

Authors:  Caroline Dufour; Pierre Gantner; Rémi Fromentin; Nicolas Chomont
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 3.  Genome editing and the next generation of antiviral therapy.

Authors:  Daniel Stone; Nixon Niyonzima; Keith R Jerome
Journal:  Hum Genet       Date:  2016-06-08       Impact factor: 4.132

4.  Immunochemical engineering of cell surfaces to generate virus resistance.

Authors:  Jia Xie; Devin Sok; Nicholas C Wu; Tianqing Zheng; Wei Zhang; Dennis R Burton; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-10       Impact factor: 11.205

5.  Excision of Latent HIV-1 from Infected Cells In Vivo: An Important Step Forward.

Authors:  Harshana S De Silva Feelixge; Keith R Jerome
Journal:  Mol Ther       Date:  2017-04-24       Impact factor: 11.454

6.  HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site.

Authors:  Zhen Wang; Wenzhou Wang; Ya Cheng Cui; Qinghua Pan; Weijun Zhu; Patrick Gendron; Fei Guo; Shan Cen; Michael Witcher; Chen Liang
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 7.  Novel AIDS therapies based on gene editing.

Authors:  Kamel Khalili; Martyn K White; Jeffrey M Jacobson
Journal:  Cell Mol Life Sci       Date:  2017-02-16       Impact factor: 9.261

8.  Evolution of Resistance Against CRISPR/Cas9 Gene Drive.

Authors:  Robert L Unckless; Andrew G Clark; Philipp W Messer
Journal:  Genetics       Date:  2016-12-10       Impact factor: 4.562

9.  The Impact of DNA Topology and Guide Length on Target Selection by a Cytosine-Specific Cas9.

Authors:  Tsz Kin Martin Tsui; Travis H Hand; Emily C Duboy; Hong Li
Journal:  ACS Synth Biol       Date:  2017-03-20       Impact factor: 5.110

10.  In vitro modeling of HIV proviral activity in microglia.

Authors:  Lee A Campbell; Christopher T Richie; Yajun Zhang; Emily J Heathward; Lamarque M Coke; Emily Y Park; Brandon K Harvey
Journal:  FEBS J       Date:  2017-11-08       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.